Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market - Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • Mar 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market, By Drugs  (Victoza, Trulicity, Byetta, Bydureon, Lyxumia, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others),  Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa), Market Trends and Forecast to 2027.

Glucagon-Like Peptide 1 (GLP-1) Agonists Market

Market Analysis and Insights: Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market

Global glucagon-like peptide 1 (GLP-1) agonists market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of type 2 diabetes worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of type 2 diabetes, obesity and related disorders drives the global glucagon-like peptide 1 (GLP-1) agonists market. Adaptation of unhealthy lifestyle and genetic history of diabetes disorders which increases the risk of evolving diabetes also boosts up the global glucagon-like peptide 1 (GLP-1) agonists market growth. In addition, the availability of the treatment is also witnessing the growth of this market. Increasing prevalence of diabetes and related disorders, government awareness programs among the people, which are accepted to drive the global glucagon-like peptide 1 (GLP-1) agonists market. However, stringent FDA and other regulatory guidelines for the approval of new drug may hamper the market growth of global glucagon-like peptide 1 (GLP-1) agonists market.

Glucagon-like peptide 1 (GLP-1) agonists also known as incretin mimetics, these agents are used for the treatment of type 2 diabetes. GLP-1 is naturally occurring peptide produces in the intestinal tract in response to the food. These agents act by stimulation of insulin production by beta cell, which reduces the postprandial increase in glucagon after eating. Both these phenomenon decreases the glucose level in the blood and slow down the gastric emptying.

Global glucagon-like peptide 1 (GLP-1) agonists market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market Scope and Market Size

Glucagon-like peptide 1 (GLP-1) agonists market is segmented on the basis of drugs, route of administration, end-users, distribution channel and others.  

  • On the basis of drugs, glucagon-like peptide 1 (GLP-1) agonists market is segmented into victoza, trulicity, byetta, bydureon, lyxumia, and others.
  • Route of administration segment of glucagon-like peptide 1 (GLP-1) agonists market is segmented into oral, parenteral and others.
  • On the basis of end-users, glucagon-like peptide 1 (GLP-1) agonists market is segmented into hospitals, specialty clinics and others.
  • On the basis of distribution channel, glucagon-like peptide 1 (GLP-1) agonists market has also been segmented into hospital pharmacy, retail pharmacy others.

Glucagon-Like Peptide 1 (GLP-1) Agonists Market Country Level Analysis

Global glucagon-like peptide 1 (GLP-1) agonists market is analyzed and market size information is provided by country, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the glucagon-like peptide 1 (GLP-1) agonists market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America dominates the market share due to increasing healthcare and R&D expenditure, patient awareness and global players on novel technology or formulation of existing drugs plays major role for the growth of glucagon-like peptide 1 (GLP-1) agonists market. Asia-Pacific is expected to account for the largest market share over coming years for the glucagon-like peptide 1 (GLP-1) agonists market due to high prevalence cases of diabetes and related disorders and number of generic drugs while, Europe is considered to hold bright growth prospects in the coming years by expanding the expenditure on the healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global glucagon-like peptide 1 (GLP-1) agonists market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Glucagon-Like Peptide 1 (Glp-1) Agonists Market Share Analysis

Global glucagon-like peptide 1 (GLP-1) agonist’s market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to glucagon-like peptide 1 (GLP-1) agonists market.

The market competitors currently working on the glucagon-like peptide 1 (GLP-1) agonists market are Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca, Sanofi, Hoffmann-La Roche Ltd. and among.

Customization Available: Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions